Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Dec. 28, 2012	Dec. 30, 2011
Cash flows from operating activities:
Net loss	$ (3,305,000)	$ (1,048,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	583,000	806,000
Amortization	876,000	1,028,000
Stock based compensation expense	124,000	480,000
Change in fair value of warrant liability	(26,000)	(719,000)
Changes in operating assets and liabilities:
Receivables - net	769,000	665,000
Inventories	(108,000)	451,000
Prepaid expenses and other assets	(212,000)	(44,000)
Accounts payable and accrued expenses	170,000	(1,468,000)
Net cash provided by (used in) operating activities	(1,129,000)	151,000
Cash flows from investing activities:
Capital expenditures	(316,000)	(543,000)
Change in restricted cash		500,000
Patent expenditures	(98,000)	(159,000)
Net cash used in investing activities	(414,000)	(202,000)
Cash flows from financing activities:
Proceeds on bank term loan		998,000
Payments on bank term loan	(250,000)	(727,000)
Net payments on bank line of credit	(500,000)	(494,000)
Payments on MEDC/MSF term loan	(397,000)	(425,000)
Payments on related parties debt		(449,000)
Proceeds from exercise of stock options		25,000
Net cash used in financing activities	(1,147,000)	(1,072,000)
Net decrease in cash and cash equivalents	(2,690,000)	(1,123,000)
Cash and cash equivalents at beginning of period	3,249,000	4,744,000
Cash and cash equivalents at end of period	559,000	3,621,000
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 81,000	$ 144,000